Cardiac Devices
Recent findings in cardiac devices described
Published in Cardiovascular Week, December 5th, 2005
Study 1: Universal use of dual-chamber implantable cardioverter defibrillators (ICDs) is a cost-effective approach.
In a recent study, cardiologists in the United States sought "to determine the least expensive strategy for device selection" in patients receiving ICDs.
"Device cost for a single-chamber ICD is less than an atrioventricular (dual-chamber) ICD (AV-ICD); however, some patients without clinical need for AV-ICD at implantation might require a later upgrade, potentially offsetting the initial cost advantage of the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
Source: Cardiovascular Week (2005-12-05)
More Articles from Cardiovascular Week
- Angiology
Perivascular adipose tissue controls vascular function in internal thoracic artery - Cardiovascular Disease
G allele in adiponectin gene at SNP 276 may indicate higher CV disease risk - Cardiovascular Disease
Hemodialysis-unresponsive BP patients are more likely to have vascular disease - Cardiovascular Research
Aortic valve calcification is associated with age, HT, and bone mineral density - Kawasaki Disease
Researchers zero in on the possible cause of Kawasaki disease - Acute Peripheral Arterial Occlusion
European Medicines Agency grants orphan drug designation for alfimeprase - More from this issue of Cardiovascular Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
